Director (Head), Global RWE & Epidemiology CoE | Top Oncology Pharma | NJ / PA Metro Area: RETAINED SEARCH

Cornerstone Search Group
Published
February 18, 2021
Location
Greater New York City Area, United States of America
Category
Job Code
caRWEepi3001
Contact Email
cackerman@cornerstonesg.com

Description

Director (Head), Global RWE & Epidemiology CoE | Top Oncology Pharma | NJ / PA Metro Area: RETAINED SEARCH

Cornerstone Search Group’s HEOR/RWE/Market Access Practice has been retained by the Head of HEOR/RWE/Epi (whom we have known for 10+ years) at one of the industry’s most exciting and fastest growing oncology biotechs (multiple approved biologics, 15+ asset pipeline, 75%+ increase in stock price in last 12 months) for a highly attractive Director-level position to build up and lead their internal RWE and Epidemiology capabilities. This multi-faceted role will include developing our client’s RWD strategy, developing their RWE operations/platforms/dashboards, working with HEOR assets leaders on RWE strategy, supporting Drug Safety on their drug risk assessment efforts, etc.

 4 HIGHLY ATTRACTIVE FEATURES OF THIS OPPORTUNITY:

 (1) “Best of Both Worlds”: Enjoy the benefit of working in a smaller, entrepreneurial, fast-moving environment where you will work with senior management while simultaneously enjoy the stability and security of working for a highly successful company with the stability afforded by their financial strength (large market cap, fast growing stock price, billion+ in revenue,) are that of a much larger company), and a huge and innovative pipeline that has attracted strong industry veterans from top large pharmas.

 (2) Innovative Self-Discovered 15+ Asset Pipeline: Our client’s vast pipeline is self-developed and built upon their own multiple antibody engineering platforms. Their monoclonal antibody, ADC, and bi-specific antibody therapeutics are all cutting edge and designed to provide a significant advancement in patient care.

 (3) Company’s Stock Performance: Our client is one of the strongest performing pharma stocks over the last 5 years, including a 75%+ gain in the last 12 months. In comparison, most large pharma stocks have stagnated over the last couple of years. Our client is very proud of providing their employees with significant stock awards (far superior to Big Pharma) so that their team feels really valued for the role they will play in building the company’s future.

(4) Employer of Choice: Their fast-rising stock price, top-tier annual stock awards (far superior to what Big Pharma provides), robust and diverse next-generation self-discovered pipeline, their financial strength, and their culture has made our client one of the industry’s “Employers of Choice”. This is a tremendously exciting opportunity to join this era’s Regeneron / Celgene / Vertex and build up the CORE department to define the future.

LOCATION: Central New Jersey

Our client is conveniently located for people who live in New Jersey and Pennsylvania. This scenic area of New Jersey is home to many other pharma and biotech companies, affordable housing options (a lot less expensive than California or Massachusetts), and is considered to have some of the best public-school districts in the country.

RELOCATION: Our client can offer an attractive relocation plan for a post-COVID 19 relocation. In the meantime, our client is not requiring people to work on-site.

SCOPE OF RWE AND EPI RESPONSIBILITIES:

  • Develop company’s real world data strategy.
  • As a key foundational block of the CORE (Center for Outcomes Research, Real World Evidence, and Epidemiology) department, you will be counted upon by the Head of CORE (whom this position reports to) to contribute to department strategy and objectives as well as represent CORE on key initiatives.
  • Develop their RWE platforms with external RWE partner.
  • Partner with HEOR asset leads on the development and execution of RWE studies.
  • Educate the organization on applicable regulations to the execution of RWE and Epidemiology.
  • Define and implement Observational Study Review Committee that will be responsible for the scientific review of observational studies.
  • Foster learning and drive RWE innovation through developing awareness and the application of impactful use cases of RWE.
  • Develop scientific standards and infrastructure for pre-and post-approval drug risk assessment (e.g.: Post-Marketing Surveillance and PASS studies using observational study designs) and the evaluation of risk management activities.
  • Define and develop operational infrastructure needs and standards for post-approval prospective observational studies.
  • Support assets by generating the evidence in a strategic manner for: (1) assessing product safety, risk management, post-marketing safety; and (2) input into regulatory documents that require epidemiologic expertise (e.g.: RMP, DSUR, PBRER)

DESIRED SKILLS / QUALIFICATIONS / EXPERIENCE:

  • PhD / PharmD / MPH / MS degree in relevant field (Epidemiology, Health Services Research, Statistics, etc.)
  • Seeking 5+ years of relevant experience in the direct conduct of RWE / Epi studies either for a pharmaceutical company, an agency / CRO / consulting company working with pharma clients, a managed care company, or in academia.
  • Operational knowledge of RWE platforms and dashboards.
  • Knowledge of PASS/PMS/PAES studies.
  • History of peer-reviewed publications.
  • Oncology experience is a plus, but not required.

DESIRED PERSONAL TRAITS:

  • Seeking someone with a strategic clinical and commercial mindset, leadership capabilities, quality communication skills, a desire to work in a fast-paced environment, and a pro-active desire to build the company’s in-house RWE and Epi capabilities.
  • Seeking someone who will fit in with their culture: people who are passionate about what they do, self-motivated, desire to make an impact, and want to work on an innovative pipeline that significantly advances the standard of care for cancer patients.
  • The ability to communicate technical information in a clear, concise, and non-techy way to diverse audiences (C-level, Commercial, Med Affairs, etc.) and effectively manage internal and external stakeholder expectations.

CONTACT:

Corey S. Ackerman, JD | Senior Partner

E: cackerman@cornerstonesg.com

P:  973.656.0220 x 716

LinkedIn: www.linkedin.com/in/coreyackerman

Rita Boyle | Partner

E: rboyle@cornerstonesg.com

P: 973.656.0220 x735

LinkedIn: https://www.linkedin.com/in/ritaboyle

CORNERSTONE SEARCH GROUP - Life Sciences Executive Search

Six Campus Drive | Suite 301 | Parsippany, New Jersey 07054 USA

www.cornerstonesg.com

USA: 973.656.0220

Examples of Retained Search Assignments:

  • CEO | specialty start-up
  • US CEO | established European small pharma
  • CMO | late-stage public biotech
  • CMO | mid-size pharma
  • CSO | mid-size global biotech
  • President/US Commercial Head | OSD generics
  • SVP, Head of Global Medical Affairs | mid-size oncology company
  • SVP, Head of Global Regulatory Affairs | late-stage Israeli biotech
  • Group VP, Global Commercial Head | API Business Unit | Indian pharma
  • VP, Global Head of Biometrics | NYC commercial-stage biotech
  • VP, Head of Regulatory Affairs | Boston biotech
  • VP, Head of Regulatory Affairs | NYC commercial-stage biotech
  • VP, Head of R&D Operations | Boston biotech
  • HEOR / RWE / Market Access - over 150 placements including assignments for: (1) VP, Head of Health Economics & Outcomes Research | Top CNS specialty pharma; (2) VP, Head of Real-World Evidence | Top 5 pharma | (3) VP, Head of US HEOR | Top 10 Pharma
  • VP, Head of Heme/Onc Clinical Research | Public oncology biotech
  • Executive Director, Head of Global Clinical Pharmacology | Public oncology biotech
  • Executive Director, Head of Global Clinical Pharmacology | Public oncology biotech
  • Executive Director, Head of US Drug Safety & PV | Chinese oncology biotech
  • Medical Director, Clinical Development | Boston biotech
  • Medical Director, Translational Medicine, Neuroscience | Top 5 Biotech

keywords: real-world RW senior director, executive director, mAb, monoclonal antibody, bsab, bispecific, bi-specific, antibody drug conjugates, ADC, immune-onc, immuno-onc, immuno oncology, IO, breast cancer, lung cancer, NSCLC, ovarian cancer, cervical cancer, bladder cancer, colon cancer

Apply
Drop files here browse files ...
PDF and .doc resume uploads are preferred. docx files are not supported.
Captcha